A Study to Test How BI 765063 is Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

• Status: Not yet recruiting
• Trial end date: 2023-03-06

Summary

This study is open to adults with advanced head and neck cancer, skin cancer, or non-small cell lung cancer. People can take part if previous treatments were not successful.

The purpose of this study is to find out how a medicine called BI 765063 is taken up in the tumours and how it gets distributed in the body. In addition to BI 765063, participants also receive ezabenlimab. BI 765063 and ezabenlimab are antibodies that may help the immune system fight cancer. Such therapies are also called immune checkpoint inhibitors.

Participants get BI 765063 and ezabenlimab as an infusion into a vein every 3 weeks. In the first weeks, doctors check how BI 765063 is taken up in tumours. To do so, the doctors use imaging methods (PET/CT scans). For this, participants get BI 765063 injected in a labelled form up to 2 times.

Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors regularly check participants' health and take note of any unwanted effects.

• Phase: Phase 1

Details

• Lead Sponsor: Boehringer Ingelheim